Skip to main navigation Skip to search Skip to main content

Synaptosomal-Associated Protein 25 kDA (SNAP-25) Levels in Cerebrospinal Fluid: Implications for Alzheimer's Disease Diagnosis and Monitoring

  • Sofia Hjorth Wolner
  • , Helena Sophia Gleerup
  • , Christian Sandøe Musaeus
  • , Peter Høgh
  • , Nicholas J Ashton
  • , Ann Brinkmalm
  • , Johanna Nilsson
  • , Lana Grötschel
  • , Henrik Zetterberg
  • , Kaj Blennow
  • , Steen Gregers Hasselbalch
  • , Anne Byriel Walls
  • , Anja Hviid Simonsen*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Synaptic degeneration has been linked to cognitive decline. The presynaptic protein, synaptosomal-associated protein 25 kDA (SNAP-25), is crucial for synaptic transmission and has been suggested as a biomarker in Alzheimer's disease (AD). In the current study, we investigated the ability of SNAP-25 to differentiate between heterogenous dementia etiologies and whether SNAP-25 could be a staging marker in AD. SNAP-25 in the cerebrospinal fluid (CSF) from a retrospective (n = 187) and a prospective (n = 134) cohort was investigated with immunoprecipitation mass spectrometry (IP-MS) and single-molecule array (Simoa), respectively. Both cohorts consisted of healthy controls (HC) and patients with cognitive decline of different etiologies. CSF SNAP-25 concentration was higher in AD and non-neurodegenerative diseases (i.e., vascular dementia) compared with controls but did not differ between AD and non-AD neurodegenerative diseases. We found a trend toward an association between SNAP-25 and disease burden when comparing HC, mild cognitive impairment due to AD, and AD. CSF SNAP-25 concentrations were strongly associated with CSF phosphorylated tau (p-tau) concentrations, thus strengthening the link between synaptic dysfunction and tau pathophysiology in AD. Our initial findings suggest that SNAP-25 may be a potential biomarker for differentiating AD from dementia due to other etiologies. However, due to the significant association between SNAP-25 and p-tau proteins, the clinical utility of SNAP-25 as a diagnostic biomarker for AD may be limited, while SNAP-25 may be useful for monitoring disease progression or treatment response.

Original languageEnglish
Article numbere70010
Number of pages9
JournalSynapse
Volume79
Issue number2
DOIs
Publication statusPublished - Mar 2025

Funding

FundersFunder number
Kirsten and Freddy Johansen Foundation, Copenhagen
Absalon Foundation
Swedish Research Council2017-00915, 2022-00732
European Union (HORIZON Europe SERENA project)101053962
Swedish Research CouncilALFGBG-71320
Alzheimer Drug Discovery Foundation201809-2016862
Swedish Alzheimer Foundation2022-2025, SG-23-1038904 QC
Cure Alzheimer's Fund
Olav Thon Foundation
Erling-Persson Family Foundation
Familjen Roenstroems Stiftelse
Stiftelsen foer Gamla Tjaenarinnor
Swedish Brain FoundationFO2017-0243, ALZ2022-0006
European UnionJPND2021-00694
NIHR University College London Hospitals Biomedical Research Centre
University College LondonUKDRI-1003
Swedish Alzheimer FoundationAF-930351, AF-939721, AF-968270, AF-994551
County CouncilsALFGBG-715986, ALFGBG-965240
European Union Joint Programme for Neurodegenerative DisordersJPND2019-466-236
National Alzheimer's AssociationZEN-21-848495
La Fondation Recherche Alzheimer
Familjen Roenstroems Stiftelse

    Keywords

    • Synaptosomal-Associated Protein 25/cerebrospinal fluid
    • Alzheimer Disease/cerebrospinal fluid
    • Humans
    • Aged
    • Female
    • Male
    • Middle Aged
    • Biomarkers/cerebrospinal fluid
    • Retrospective Studies
    • Cognitive Dysfunction/cerebrospinal fluid
    • tau Proteins/cerebrospinal fluid
    • Prospective Studies
    • Aged, 80 and over
    • Snap-25
    • Csf
    • Diagnosis
    • Alzheimer's disease

    Fingerprint

    Explore the research areas of 'Synaptosomal-Associated Protein 25 kDA (SNAP-25) Levels in Cerebrospinal Fluid: Implications for Alzheimer's Disease Diagnosis and Monitoring'.

    Cite this